Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21

Ida Bruun Kristensen, Hanne Norseth, Diana Loigom, Henrik Gregersen, Tobias S. Slørdahl, Robert Pedersen, Einar Haukås, Damian Szatkowski, Dennis Hansen, Fredrik Schjesvold, Thomas Lund

Blood (2025) 146 (Supplement 1): 4034.

https://doi.org/10.1182/blood-2025-4034

Published: 2025

Journal Articles

Optimizing lenalidomide therapy in renal impairment: Analysis of renal response in the prospective remnant study in transplant-eligible newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 4032.

https://doi.org/10.1182/blood-2025-4032

Published: 2025

Journal Articles

Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; Results from the nmsg rest study

Lene Kongsgaard Nielsen, Tine Rosenberg, Andreas Kristian Pedersen, Claudia Routherford, Tracy King, Mararet-Ann Tait, Einar Haukaas, Tobias S. Slørdahl, Anja Klostergaard, Emil Hermansen, Fredrik Schjesvold, Frida Bugge Askeland

Blood (2025) 146 (Supplement 1): 2785.

https://doi.org/10.1182/blood-2025-2785

Published: 2025

Journal Articles

PRL-3 enhances multiple myeloma cell survival in acidic microenvironments via metabolic adaptation and pH regulation.

Henrik Marius Laukli, Rifaquat Ahmed, Eli Hess, Intira Saman, Daniel Edvin Schjerpen, Tobias S. Slørdahl, Magne Borset

Blood (2025) 146 (Supplement 1): 5714.

https://doi.org/10.1182/blood-2025-5714

Published: 2025

Journal Articles

Risk of returning to work and disability pension in multiple myeloma patients in central Norway

Håkon Skjalg Selland Johnstuen, Torstein Kleveland, Tobias S. Slørdahl

Blood (2025) 146 (Supplement 1): 7920.

https://doi.org/10.1182/blood-2025-7920

Published: 2025

Journal Articles

Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study

Frida Bugge Askeland, Anne-Marie Rasmussen, Anna Lysen, Einar Haukås, Anette Løken Eilertsen, Magnus Moksnes, Galina Tsykunova, Anders Vik, Birgitte Dahl Eiken, Vidar Stavseth, Jürgen Rolke, Eivind Ottersen Samstad, Valdas Peceliunas, Randi Fykse Hallstensen, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Fredrik Schjesvold

Blood (2023) 142 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2023-189022

Published: 2023

Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Diana Schjøll, Anna Lysen, Emil Hermansen, Fredrik Schjesvold

Blood (2023) 142 (Supplement 1): 3381.

https://doi.org/10.1182/blood-2023-173126

Published: 2023

Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Diana Schjøll, Anna Lysén, Emil Hermansen, Fredrik Schjesvold

Blood (2022) 140 (Supplement 1): 12623–12625.

https://doi.org/10.1182/blood-2022-156625

Published: 2022

Journal Articles

Monoclonal immunoglobulins promote bone loss in multiple myeloma

Marita Westhrin, Vlado Kovcic, Zejian Zhang, Siv H. Moen, Tonje Marie Vikene Nedal, Albert Bondt, Stephanie Holst, Kristine Misund, Glenn Buene, Anders Sundan, Anders Waage, Tobias S. Slørdahl, Manfred Wuhrer, Therese Standal

Blood (2020) 136 (23): 2656–2666.

https://doi.org/10.1182/blood.2020006045

Published: 2020

Includes: Supplemental data

Journal Articles

The Serine Protease Matriptase Acts As a Tumour Suppressor in Multiple Myeloma

Ida Steiro, Pegah Abdollahi, PhD, Magne Børset, MD PhD, Tobias S. Slørdahl, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140229

Published: 2020

Journal Articles

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Marita Westhrin, Vlado Kovcic, Albert Bondt, Stephanie Holst, Zejian Zhang, Anders Sundan, PhD, Tobias S. Slørdahl, Anders Waage, MD PhD, Manfred Wuhrer, Therese Standal

Blood (2019) 134 (Supplement_1): 4324.

https://doi.org/10.1182/blood-2019-122542

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21

Optimizing lenalidomide therapy in renal impairment: Analysis of renal response in the prospective remnant study in transplant-eligible newly diagnosed multiple myeloma

Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; Results from the nmsg rest study

PRL-3 enhances multiple myeloma cell survival in acidic microenvironments via metabolic adaptation and pH regulation.

Risk of returning to work and disability pension in multiple myeloma patients in central Norway

Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Monoclonal immunoglobulins promote bone loss in multiple myeloma

The Serine Protease Matriptase Acts As a Tumour Suppressor in Multiple Myeloma

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only